Table II.
Correlation between clinicopathologic characteristics and PKM2 expressiona.
| Clinicopathological variables | Total | Odds ratio (95% CI) | P-value |
|---|---|---|---|
| Sex (male vs. female) | 370 | 2.407 (1.537–3.771) | <0.001 |
| Diagnosis age (continuous) | 370 | 0.988 (0.973–1.003) | 0.130 |
| BMI (continuous) | 334 | 0.985 (0.951–1.020) | 0.394 |
| Creatinine (continuous) | 298 | 0.962 (0.911–1.015) | 0.153 |
| Fetoprotein (continuous, log2 converted) | 277 | 1.157 (1.091–1.228) | <0.001 |
| Albumin (continuous) | 295 | 0.961 (0.899–1.026) | 0.233 |
| Residual tumor (R0 vs. R1 or R2) | 364 | 2.293 (1.142–4.601) | 0.020 |
| Vascular tumor invasion (none vs. micro or macro) | 315 | 1.521 (0.954–2.425) | 0.078 |
| Adjacent hepatic tissue inflammation (none vs. mild or severe) | 234 | 1.000 (0.598–1.673) | >0.999 |
| Stage (I or II vs. III or IV) | 348 | 1.857 (1.141–3.021) | 0.013 |
| Grade (1 or 2 vs. 3 or 4) | 366 | 2.010 (1.303–3.100) | 0.002 |
a
Categorical dependent variable, greater or less than the median expression level (11.25). PKM2, pyruvate kinase muscle isozyme M2; CI, confidence interval; BMI, body mass index.